Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

NCT02162888 is registered in ClinicalTrials.gov with Eagle Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02162888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02162888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients
Lead sponsor
Eagle Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
November 30, 2014
Enrollment
81 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer which has either progressed or relapsed after standard therapy, or for which no curative or standard therapy is appropriate